Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The agreement was formally signed yesterday.
Investment in Michigan Facility Targets Future Growth for High-Demand Natural Insecticide Technology
GAAP earnings per share (EPS) from continuing operations was a loss of $(0.69) for the third quarter and operating EPS1 was a loss of $(0.39) – both improved compared to prior year.
Further German cooperation with the Paracelsus Clinic in Zwickau and first NanoTherm treatment center outside of Germany opened at the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland
MorphoSys AG reported its financial results for the third quarter of 2019.
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
BioVersys AG announced, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.
Financing will support Sense’s development of instrument-free molecular diagnostics aimed at true point-of-care testing
Sense Biodetection Limited raises £12.3m to progress instrument-free molecular diagnostics
Initial focus on diagnosing infectious disease through development of machine-free, lab-quality, True Point-of-Care™ products